• Roivant unit Priovant enrolled first patients in a Phase 3 trial of brepocitinib for cutaneous sarcoidosis, a condition with no approved therapies.
• Results will be presented in the future, with BEACON+ topline data expected in 2028.
• The study follows a positive Phase 2 outcome that supported FDA Breakthrough Therapy Designation, positioning brepocitinib as a potential new treatment option.
• Priovant expects a U.S. regulatory decision in dermatomyositis by end-September 2026, supporting a near-term launch path for the drug.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.